Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AST-1138
- Development stage
- Unknown
- Lead developer
- Aston
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
AST-1138 is an investigational therapeutic vaccine and mRNA vaccine targeting KRAS, specifically developed as a KRAS modulator. Its mechanism of action involves modulation of the GTPase KRas protein (KRAS), which is a well-known oncogenic driver in various cancers. The drug is being developed by Aston SCI for the treatment of neoplasms associated with KRAS mutations, particularly KRAS mutation-related tumors. As of June 2025, its highest development status is at the Discovery stage[1].
02
Targets
Beyond the preview
Go deeper on AST-1138.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AST-1138.